Hormon alan trans kadınlarda erkeklerin 4,5 katı kan pıhtısı ve daha çok inme; trans erkeklerde daha çok kalp krizi

Hormon tedavisi gören transseksüel bireylerde akut kardiyovasküler olayların görülmesi

Kohort & kayıt çalışmaları Karşı cins hormonları

Authors: Nienke M. Nota, Chantal M. Wiepjes, Christel J.M. de Blok, Louis J.G. Gooren, Baudewijntje P.C. Kreukels, Martin den Heijer
Journal: Circulation
Year: 2019
Source: https://doi.org/10.1161/CIRCULATIONAHA.118.038584

Summary

This short report used records from the Amsterdam gender clinic, which treats most trans people in the Netherlands. It counted strokes, heart attacks and blood clots in nearly 3,900 people on cross-sex hormones over about 8 to 9 years, and compared them with expected rates in the general population. Trans women had about 4.5 to 5.5 times the expected rate of blood clots and about twice the expected rate of stroke, and more heart attacks than women (but not men). Trans men had more heart attacks than women but about the same as men. Blood-clot risk was lower, though still raised, in trans women who started after 2001, when an older estrogen was dropped. The long follow-up makes this useful, but the comparison is with outside population figures, smoking was not accounted for, and the trans men's results rest on few events.

Key findings

Çalışma, Amsterdam cinsiyet kliniğinde tedavi edilen, ortalama yaklaşık 9 ve 8 yıl izlenen 2.517 trans kadını ve 1.358 trans erkeği kapsadı.
Trans kadınlarda damarlarda 73 kan pıhtısı görüldü: kadınlarda beklenen oranın 5,5 katı ve erkeklerinkinin 4,5 katı.
Trans kadınlarda 29 felç (kadınlardaki oranın 2,4 katı, erkeklerinkinin 1,8 katı) ve 30 kalp krizi (kadınlardaki oranın 2,6 katı; erkeklere göre yüksek değil) görüldü.
Trans erkeklerde 11 kalp krizi görüldü: kadınlarda beklenen oranın 3,7 katı ve erkeklerde beklenenle aynı.
Trans erkeklerde yalnızca 6 felç ve 2 kan pıhtısı vardı; erkeklerle ya da kadınlarla açık bir fark yoktu.
2001'den önce başlayan (eski bir östrojen olan etinilestradiolün değiştirildiği zaman) trans kadınları dışarıda bırakmak, kan pıhtısı oranını kadınlarınkinin yaklaşık 3,9 katına ve erkeklerinkinin 3,4 katına düşürdü; diğer riskler düşmedi.
Çalışmadaki kişilerin %43-46'sı sigara içiyordu ve bunun için düzeltme yapılamadı.

Conclusion

Considering the limitations, the authors conclude that the incidences of strokes and VTEs are higher in transwomen receiving hormone therapy than in both reference women and men, and that transwomen and transmen receiving hormone therapy are at higher risk of myocardial infarction than reference women. They urge physicians and transgender individuals to be aware of this increased cardiovascular risk and to reduce risk factors such as smoking.

Methodological limitations

Very short report: It was published as a two-page letter with few details, so how events were defined, who was left out and how results were checked are only briefly described.
Outside comparison only: Rates were compared with figures from separate Dutch and Norwegian population studies that found cases in different ways, not with a matched group of similar people.
Other risk factors ignored: The authors could not account for smoking (43–46% smoked) or life stresses, and weight, diabetes and other risk factors were not accounted for either.
Events may have been missed: Events were found by searching clinic files for doctors' letters. Events treated elsewhere and not reported back may have been missed, so true rates are probably higher.
Older drugs: Much of the follow-up involved older drugs (ethinylestradiol and high-dose cyproterone). Leaving out early starters lowered blood-clot risk, so the headline figure overstates risk on today's drugs, though risk was still raised.
Few events in trans men: Results rest on 6 strokes, 11 heart attacks and 2 blood clots, so the figures are very uncertain.
Some people left out: People who stopped hormones for long periods or switched between male and female hormones (such as some detransitioners) were excluded, as were 52 people with a past event.
Uneven follow-up: The typical person was followed for only about 4 to 6 years, much less than the average, so much of the data comes from a minority treated for a long time.
One clinic: Everyone was treated at one specialist centre, so results may not apply outside the Netherlands.

detrans.ai

Summary

Key findings

Conclusion